Current challenges in screening for pancreatic ductal adenocarcinoma: an appraisal of the METAPAC study
Translational Gastroenterology and Hepatology · 2026-07 · 11 · 83-83
DOI: 10.21037/tgh-2026-0049 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-07. Verfasst von Omar Mahmud und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY, USA. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY, USA.
- Medical College, The Aga Khan University, Karachi, Pakistan.
Zitieren
APA
Mahmud, O., Fatimi, A. S., & Javed, A. A. (2026). Current challenges in screening for pancreatic ductal adenocarcinoma: an appraisal of the METAPAC study. Translational Gastroenterology and Hepatology, 11, 83-83. https://doi.org/10.21037/tgh-2026-0049
Vancouver
Mahmud O, Fatimi AS, Javed AA. Current challenges in screening for pancreatic ductal adenocarcinoma: an appraisal of the METAPAC study. Translational Gastroenterology and Hepatology. 2026;11:83-83. doi:10.21037/tgh-2026-0049
BibTeX
@article{Mahmud2026,
author = {Mahmud, Omar and Fatimi, Asad Saulat and Javed, Ammar A},
title = {Current challenges in screening for pancreatic ductal adenocarcinoma: an appraisal of the METAPAC study},
journal = {Translational Gastroenterology and Hepatology},
year = {2026},
volume = {11},
pages = {83--83},
doi = {10.21037/tgh-2026-0049}
}
EUVIMED